The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Imara Inc. today announced it will report additional preclinical and Phase 1 clinical data from the company’s lead compound, IMR-687, a once-daily, oral therapy ...

Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data ...

Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing and building breakthrough biotech companies, notes that its portfolio company Imara, Inc. ("Imara") has ...

IMR-687 is an investigational, orally administered, highly potent and selective phosphodiesterase 9 (PDE9) inhibitor currently being evaluated as a potential disease-modifying therapeutic for sickle ...